MEMY - Sector: Healthcare --- Industry: Biotechnology & Drugs

[setravis]

Anyone still messing with this one ?
Active in the pre-market.
+23.04%.........Volume @.......240,887

News out Link.........  http://finance.yahoo.com/q/h?s=MEMY

HEADLINES 
[audio] Memory Pharmaceuticals Announces Preliminary Results from Safety and Tolerability Study for MEM 1003 in Alzheimer's Patients (live today at 9:00 am ET)


• Memory Pharmaceuticals Announces Preliminary Results from Safety and Tolerability Study for MEM 1003 in Alzheimer's Patients Call scheduled for 9:00 am ET today
CCBN (Tue 8:10am) 

[higherstocks]

Watch this mo;rning!!!! 

[domination]

it's on my radar setravis

[Keichi]

golden cross about to cross. ER feb. 21

http://stockcharts.com/def/servlet/SC.web?c=MEMY,uu[r,a]daclyyay[dc][pc9!c20!b40!b50!b200!c200!i!f][vc60][iUc20!Ua12,26,9!Lb14!Ld20!Lf!Lg!Lh14,3!Li14,3!Lp14,3,3!Lk14!Ll14!Lo14!Lv25]&pref=G

thanks

[1reilly]

I've been accumulating this stock for the last two months between 2.39 & 2.45. Last week some volume started showing up and you can see by those 3 white candles that someone is buying this stock. I bring this up now because Fri the bias was to the buy side with the stck actually putting out the interday high in the last 15 minutes. What has me interested is the way the MM posted a close outside the 2.70 bid. It was very important to somebody not to have that close above 2.69. This looks like a stock that has waded through sellers around the 2.62 level. I'm looking for this to take out the 2.75-2.85 Level.

[1reilly]

My last post showed those three white candles. Take a look a this, somebody is very quietly buying this stock. Easy downside protection. I own it and can play this by myself.Just thought I'd bring it up again.

[Terliso]

I'm experimenting a new technique (probably not new to everyone but it's new to me ) with real money, prices must close above MA(08) for me to trigger the trade & printing attractive candlestick on the chart (weekly chart)

So I bought MEMY today @ 2.82 .... Prices has been sitting above MA(08) for several weeks now.. 13 weeks to be exact (Weekly Chart) ....So let's see how this goes, I'll stop my loss if it MEMY close @ $2.60 or below

[Terliso]

Here is one example... i'll BUY siri when prices close above MA(08) -->WEEKLY CHART..

[1reilly]

Terlisa
I have recently posted on this one on the Previous 3sof board. This week will probably tell us if we're right. I do plan to hold this one unless I get a close under 2.39. No technical reason, that's my cost. I think we're close to some test data and I want to be around.

[guitarman]

Hi All
This one is showing some signs of life.
An insider buy for 100K shares a few days ago and now this>

Memory Pharmaceuticals Announces $32.2 Million Financing
         - Company Appoints Vaughn M. Kailian to Board of Directors -MONTVALE, N.J., Oct. 5 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it has entered into a definitive purchase agreement for a private placement of an aggregate of approximately 28.2 million newly issued shares of common stock at a price of $1.11 per share to Great Point Partners and MPM Capital, as well as existing institutional investors and other accredited investors. The Company will also issue warrants for the purchase of an aggregate of approximately 7.1 million additional shares of common stock at an exercise price of $1.33 per share to these investors. The financing will raise gross proceeds of approximately $32.2 million. Memory Pharmaceuticals intends to use the net proceeds from the financing to advance its clinical, preclinical and exploratory research programs and for other working capital and general corporate purposes.

Memory Pharmaceuticals also announced that, concurrent with the closing of the financing, Vaughn M. Kailian, a General Partner of MPM BioVentures IV, LP, will be appointed to its Board of Directors. Mr. Kailian previously served as Vice Chairperson of the Board of Directors of Millennium Pharmaceuticals, Inc. and was head of the Millennium commercial organization. Prior to that, he served as Chief Executive Officer, President and Director of COR Therapeutics, Inc. He is currently a member of the board of BIO Ventures for Global Health and the New England Healthcare Institute.

The offering is expected to close in two tranches, based on the applicability of certain Nasdaq rules. The first tranche is expected to close on or about October 16, 2006 and will result in gross proceeds of approximately $26.7 million. The closing of the second tranche may be subject to stockholder approval.

The securities being sold in this private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from the registration requirements. The shares were offered and will be sold only to qualified institutional investors and a limited number of accredited investors. Memory Pharmaceuticals has agreed to file a registration statement with the SEC covering resale of the common stock issued in the private placement and issuable upon the exercise of the warrants.


All the Best
Gman

[usedcasting]

Good eye guitarman (Appl), lots of insider buying on Oct 16th and big push yesterday, up 26% with 8 times average volume . Next stop $2.17.

uc.

[setravis]

Hmmmmmmmmm........
We missed keeping a watch on this....
We have got to keep on top things much better than this..... 

52wk Range: 0.84 - 2.93
Volume: 1,026,820
Avg Vol (3m): 222,815

Technicals
Percentage Gainer

Last Price Quote is:
37.41%above 13-day MA
65.49%above 50-day MA
RS Rating: 99 

Fundamentals
Earnings Expected on Nov 7

Key Data:
Market Cap (M): $35.60 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/07/2006
Last Analyst Rating: Sector Outperform

[setravis]

Press Release Source: Memory Pharmaceuticals Corp.


Memory Pharmaceuticals to Announce Third Quarter 2006 Results on Thursday, November 9, 2006
Thursday November 2, 9:16 am ET


MONTVALE, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) announced today that it will report its Third quarter 2006 financial results on Thursday, November 9, 2006, before the U.S. financial markets open. Management will provide a Company update and discuss the third quarter results during a conference call on Thursday, November 9, 2006, at 9:00 a.m. EST.

    Investors and other interested parties may access the call as follows:

    Date:                       Thursday, November 9, 2006
    Time:                       9:00 a.m. EST
    Telephone (U.S.):           800.299.9086
    Telephone (international):  617.786.2903
    Participant Passcode:       87308676
    Webcast:                    http://www.memorypharma.com under the
                                "Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EST on Thursday, November 9, 2006, until Thursday, November 16, 2006. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter pass code number 44660408. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer's disease, schizophrenia, depression and bipolar disorder. For additional information, please visit our website at http://www.memorypharma.com.

[kslifka]

I sat and watched this one the past few days and never bought 

Something is seriously going on with MEMY.  Volume really kicked in the last hour of the day.

[njshiva]

Dont understand.. with all these dilution why the stock is going up 

Form 8-K for MEMORY PHARMACEUTICALS CORP

20-Dec-2006

Unregistered Sale of Equity Securities, Other Events, Financial State


Item 3.02 Unregistered Sales of Equity Securities.

As previously reported in a Current Report on Form 8-K filed on October 10, 2006 by Memory Pharmaceuticals Corp. (the "Registrant"), the Registrant entered into a definitive Securities Purchase Agreement, dated October 5, 2006, for the private placement of an aggregate of approximately 28.2 million newly issued shares of common stock (the "Shares") at a price of $1.11 per share and the concurrent issuance of warrants for the purchase of an aggregate of approximately 7.1 million additional shares of common stock (the "Warrants") at an exercise price of $1.33 per share (the "Private Placement").

On October 16, 2006 the Registrant closed the first tranche of the Private Placement, selling 23,245,724 of the Shares and all 7,058,042 Warrants and raising gross proceeds of approximately $26.7 million. On December 18, 2006, the Registrant closed the second tranche of the Private Placement, selling the remaining 4,986,478 Shares and raising gross proceeds of approximately $5.5 million.

The aggregate offering price of the Shares and Warrants sold in the Private Placement is approximately $32.2 million, of which approximately $1.3 million will be paid to the placement agents for their services in connection with the Private Placement.

The Shares and the Warrants were offered and sold in reliance on exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder, based on the nature of the investors and certain representations made to the Registrant.

This Current Report on Form 8-K is neither an offer to sell nor the solicitation of an offer to buy shares of common stock or other securities of the Registrant.